IT201900023895A1 - Combinazione comprendente il composto bh3-mimetico abt-199 (venetoclax) e almeno un inibitore della produzione di nadph e/o suoi sali o derivati farmaceuticamente accettabili, composizioni farmaceutiche che comprendano tale combinazione e uso nel trattamento dei linfomi non-hodgkin a cellule b, preferibilmente nel trattamento del linfoma diffuso a grandi cellule b (dlbcl) - Google Patents

Combinazione comprendente il composto bh3-mimetico abt-199 (venetoclax) e almeno un inibitore della produzione di nadph e/o suoi sali o derivati farmaceuticamente accettabili, composizioni farmaceutiche che comprendano tale combinazione e uso nel trattamento dei linfomi non-hodgkin a cellule b, preferibilmente nel trattamento del linfoma diffuso a grandi cellule b (dlbcl)

Info

Publication number
IT201900023895A1
IT201900023895A1 IT102019000023895A IT201900023895A IT201900023895A1 IT 201900023895 A1 IT201900023895 A1 IT 201900023895A1 IT 102019000023895 A IT102019000023895 A IT 102019000023895A IT 201900023895 A IT201900023895 A IT 201900023895A IT 201900023895 A1 IT201900023895 A1 IT 201900023895A1
Authority
IT
Italy
Prior art keywords
nadph
combination
salts
pharmaceutically acceptable
pharmaceutical compositions
Prior art date
Application number
IT102019000023895A
Other languages
English (en)
Inventor
Vincenzo Ciminale
Vittoria Raimondi
Francesco Ciccarese
Original Assignee
Univ Degli Studi Padova
St Oncologico Veneto Iov Irccs
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Degli Studi Padova, St Oncologico Veneto Iov Irccs filed Critical Univ Degli Studi Padova
Priority to IT102019000023895A priority Critical patent/IT201900023895A1/it
Priority to PCT/IB2020/061684 priority patent/WO2021116929A1/en
Publication of IT201900023895A1 publication Critical patent/IT201900023895A1/it

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4162—1,2-Diazoles condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/566—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol having an oxo group in position 17, e.g. estrone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
IT102019000023895A 2019-12-13 2019-12-13 Combinazione comprendente il composto bh3-mimetico abt-199 (venetoclax) e almeno un inibitore della produzione di nadph e/o suoi sali o derivati farmaceuticamente accettabili, composizioni farmaceutiche che comprendano tale combinazione e uso nel trattamento dei linfomi non-hodgkin a cellule b, preferibilmente nel trattamento del linfoma diffuso a grandi cellule b (dlbcl) IT201900023895A1 (it)

Priority Applications (2)

Application Number Priority Date Filing Date Title
IT102019000023895A IT201900023895A1 (it) 2019-12-13 2019-12-13 Combinazione comprendente il composto bh3-mimetico abt-199 (venetoclax) e almeno un inibitore della produzione di nadph e/o suoi sali o derivati farmaceuticamente accettabili, composizioni farmaceutiche che comprendano tale combinazione e uso nel trattamento dei linfomi non-hodgkin a cellule b, preferibilmente nel trattamento del linfoma diffuso a grandi cellule b (dlbcl)
PCT/IB2020/061684 WO2021116929A1 (en) 2019-12-13 2020-12-09 Composition comprising the bh3-mimetic abt-199 (venetoclax) and at least one inhibitor of the nadph production

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IT102019000023895A IT201900023895A1 (it) 2019-12-13 2019-12-13 Combinazione comprendente il composto bh3-mimetico abt-199 (venetoclax) e almeno un inibitore della produzione di nadph e/o suoi sali o derivati farmaceuticamente accettabili, composizioni farmaceutiche che comprendano tale combinazione e uso nel trattamento dei linfomi non-hodgkin a cellule b, preferibilmente nel trattamento del linfoma diffuso a grandi cellule b (dlbcl)

Publications (1)

Publication Number Publication Date
IT201900023895A1 true IT201900023895A1 (it) 2021-06-13

Family

ID=70155025

Family Applications (1)

Application Number Title Priority Date Filing Date
IT102019000023895A IT201900023895A1 (it) 2019-12-13 2019-12-13 Combinazione comprendente il composto bh3-mimetico abt-199 (venetoclax) e almeno un inibitore della produzione di nadph e/o suoi sali o derivati farmaceuticamente accettabili, composizioni farmaceutiche che comprendano tale combinazione e uso nel trattamento dei linfomi non-hodgkin a cellule b, preferibilmente nel trattamento del linfoma diffuso a grandi cellule b (dlbcl)

Country Status (2)

Country Link
IT (1) IT201900023895A1 (it)
WO (1) WO2021116929A1 (it)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114057728A (zh) * 2020-08-06 2022-02-18 北京诺诚健华医药科技有限公司 作为bcl-2抑制剂的杂环化合物
CN114099464B (zh) * 2021-11-04 2023-09-08 国科温州研究院(温州生物材料与工程研究所) 一种治疗白血病的靶向纳米粒子及其制备方法与应用
CN114949230A (zh) * 2022-06-13 2022-08-30 厦门大学附属第一医院 一种预防和/或治疗急性髓系白血病的联合用药物组合物及其应用
CN116240283A (zh) * 2022-09-27 2023-06-09 广州市妇女儿童医疗中心 Oma1在逆转急性淋巴细胞白血病耐药中的应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015095834A2 (en) * 2013-12-20 2015-06-25 Biomed Valley Discoveries, Inc. Cancer treatments using erk1/2 and bcl-2 family inhibitors

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015095834A2 (en) * 2013-12-20 2015-06-25 Biomed Valley Discoveries, Inc. Cancer treatments using erk1/2 and bcl-2 family inhibitors

Non-Patent Citations (13)

* Cited by examiner, † Cited by third party
Title
"Handbooko 'pl78rm8ceutic8l excipients", 2009, INCORPORATED BY REFERENCE
"pharmaceutical tablets for dosage forms", 1989, MARCEL DEKKER, INC.
"Remington - the Science and practice of Pharmacy", 2000, LIPPINCOTT WILLIAMS & WILKINS
ANDERSON, M. A. ET AL.: "The BCL2 selective inhibitor venetoclax induced rapid onset apoptosis of CLL cells in patients via to TP53-independant mechanism", BLOOD, vol. 127, 2016, pages 3215 - 3224
ANSEL ET AL.: "pharmaceutical dosage forms and drug delivery systems", 1995, WILLIAMS AND WILKINS
CHOU, T. C.: "Drug combination studies and their synergy quantification using the Chou-Talalay method", CANCER RES, vol. 70, 2010, pages 440 - 446, XP055169871, DOI: 10.1158/0008-5472.CAN-09-1947
KUMARI, S.BADANA, A.. K.G, M. M.G, S.MALIA, R.: "Tumor cells could therefore be vulnerable to a further increase in ROS , which activates programd cell death (apoptosis)", BIOMARK INSIGHTS, 2018
LEVERSON JDCOJOCARI D: "Hematologic tumor Cell resistance to the BCL-2 inhibitor Venetoclax: A Product of its Microenvironment?", FRONT. ONCOL., vol. 8, 2018, pages 458
P. STAHLC. WERMUTH: "Handbook of pharmaceutical sales", 2008, WILEY-VCH, pages: 127 - 133
PERNAS, L.SRUN, L.: "Mito-Morphosis: MyTOCHONDRIAL fusion, Fission, and Cristae Remodeling as Key mediators of Cellular function", ANNU REV PHYSIOL, vol. 78, 2016, pages 505 - 531
ROBERTS AWHUANG D.: "Targeting BCL2 with BH3 Mimetics: Basic Science and Clinical Application of Venetoclax in Chronic Lymphocytic Leukemia and related B Celi Malignancies", CLIN PHARMACOL THER., vol. 101, no. 1, 2017, pages 89 - 98
SAMUEL Y NG ET AL: "Selective Bcl-2 inhibition to treat chronic lymphocytic leukemia and non-Hodgkin lymphoma", CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, vol. 12, no. 4, 1 April 2014 (2014-04-01), US, pages 224, XP055263314, ISSN: 1543-0790 *
SILIC-BENUSSI, M. ET AL.: "Selective killing of human T-ALL cells: An integrated approach targeting redox homeostasis and the OMA1/OPA1 axis", CELL DEATH DIS, vol. 9, 2018, pages 822

Also Published As

Publication number Publication date
WO2021116929A1 (en) 2021-06-17

Similar Documents

Publication Publication Date Title
IT201900023895A1 (it) Combinazione comprendente il composto bh3-mimetico abt-199 (venetoclax) e almeno un inibitore della produzione di nadph e/o suoi sali o derivati farmaceuticamente accettabili, composizioni farmaceutiche che comprendano tale combinazione e uso nel trattamento dei linfomi non-hodgkin a cellule b, preferibilmente nel trattamento del linfoma diffuso a grandi cellule b (dlbcl)
CL2011003266A1 (es) Compuestos derivados de imidazolidin-2-ona, con actividad inhibidora de 17alfa-hidroxilasa/liasa-c17,20; composicion farmaceutica que los comprende; y uso en el tratamiento de inflamacion o cancer, entre otras.
CL2022000447A1 (es) Inhibidores de kras g12d
CL2020000075A1 (es) Carboxamidas como moduladores de los canales de sodio.
CL2019001077A1 (es) Derivados de 6,7,8,9-tetrahidro-3h-pirazolo[4,3-f] isoquinolina útiles en el tratamiento del cáncer.
PH12018501807A1 (en) Pyrazolopyrrolidine derivatives and their use in the treatment of diseas
UY38979A (es) Tetrahidrofuranos sustituidos como moduladores de canales de sodio
BR112021022536A2 (pt) Derivado de fenilpropenilpiridina substituída e método de preparação do mesmo e uso médico do mesmo
UY37952A (es) Formulaciones de un inhibidor de la quinasa trk macrocíclica
CL2015002658A1 (es) Derivados de 2, 3 - disustituto 1- acil -4 amino - 1,2,3,4 tetrahidroquinilina y su uso como inhibidores de bromodominio
CL2015003135A1 (es) Derivados de 2,2-difluoropropanamida y metil bardoxolona, formas polimorficas y métodos de uso.
BR112016000561B8 (pt) Compostos terapeuticamente ativos, uso dos mesmos, composição farmacêutica e uso da mesma
BR112017007708A2 (pt) composto macrocíclicos, uso de um composto macrocíclicos, método para tratamento, unidade de dose, composição farmacêutica e método para tratar câncer em um paciente
EA201692265A1 (ru) Ингибиторы фосфатидилинозитол-3-киназы
GT201500235A (es) Estra -1,3,5 (10) , 16- tetraeno -3-carboxamidas para la inhibicion de la 17b-hidroxiesteroide deshidrogenasa (akr1c3)
PE20220017A1 (es) Inhibidores del kcnt1 y metodos de uso
BR112016016870A8 (pt) derivados de icariina, seus usos, e composição farmacêutica
SV2017005466A (es) Pirazolpiridinaminas como inhibidores de mknk1 y mknk2
UY36054A (es) “CROMENO Y 1,1a,2,7b–TETRAHIDROCICLOPROPA[C]CROMENOPIRIDOPIRAZINADIONAS NOVEDOSAS”.
BR112017020081A2 (pt) análogos deuterados de etifoxina, seus derivados e usos dos mesmos
DOP2019000100A (es) Derivados de naftiridinona y su uso en el tratamiento de la arritmia
CL2018002084A1 (es) Triterpenoides modificados en c-3 y c-17 como inhibidores del vih-1.
CO2022008817A2 (es) Macrociclos para uso en el tratamiento de enfermedades
WO2019054891A3 (en) Trpv2 antagonists
IT202000001567A1 (it) Combinazione comprendente un composto bh3-mimetico e/o suoi sali o derivati farmaceuticamente accettabili e almeno un inibitore di pik3c3/vps34 e/o suoi sali o derivati farmaceuticamente accettabili, composizioni farmaceutiche che comprendano tale combinazione e uso nel trattamento dei linfomi non-hodgkin a cellule b e nel trattamento delle leucemie linfoidi e/o mieloidi.